Based on our in vitro results showing higher binding for avelumab to PD-L1 in IFN-γ-stimulated NCIN87 gastric cancer cells compared to atezolizumab (Figures 2A, B), we conducted PET imaging and biodistribution analyses of these two antibodies in NCIN87 gastric xenografts. Here, IFNG is linked to gastric cancer.